Shepherd Kaplan Krochuk’s Supernus Pharmaceuticals SUPN Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-6,808	Closed	-$213K	–	264
2017 Q1	$213K	Sell	6,808 -2,844	-29%	-$76.2K	0.11%	159
2016 Q4	$244K	Sell	9,652 -22,451	-70%	-$502K	0.07%	151
2016 Q3	$794K	Hold	32,103	–	–	0.17%	76
2016 Q2	$654K	Hold	32,103	–	–	0.16%	83
2016 Q1	$490K	Buy	+32,103	New	+$419K	0.15%	96
2015 Q4	–	Sell	-23,462	Closed	-$329K	–	418
2015 Q3	$329K	Hold	23,462	–	–	0.09%	173
2015 Q2	$398K	Hold	23,462	–	–	0.07%	198
2015 Q1	$284K	Hold	23,462	–	–	0.05%	245
2014 Q4	$195K	Hold	23,462	–	–	0.03%	352
2014 Q3	$204K	Buy	23,462 +1,690	+8%	+$15.3K	0.03%	434
2014 Q2	$238K	Hold	21,772	–	–	0.03%	410
2014 Q1	$195K	Buy	+21,772	New	+$201K	0.02%	456

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Shepherd Kaplan Krochuk's SUPN Position: Q2 2017 in Review

Shepherd Kaplan Krochuk sold out of Supernus Pharmaceuticals (SUPN) in Q2 2017, closing a stake of 6,808 shares — an estimated $213K sold.

Shepherd Kaplan Krochuk first reported a position in SUPN in Q1 2014 and held it in 12 quarters. The position peaked at $794K in Q3 2016. 265 funds tracked by Wall St. Rank hold SUPN as of Q2 2017.

Shepherd Kaplan Krochuk reported no remaining Supernus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Shepherd Kaplan Krochuk sold 6,808 Supernus Pharmaceuticals shares in Q2 2017, an estimated $213K.
Shepherd Kaplan Krochuk first reported a position in Supernus Pharmaceuticals in Q1 2014 and held it in 12 quarters.
Shepherd Kaplan Krochuk's Supernus Pharmaceuticals position peaked at $794K in Q3 2016.
265 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2017.

Based on Shepherd Kaplan Krochuk's 13F filing for Q2 2017, filed 10 Aug 2017.